Key result
Novel inflammatory and renal biomarkers show promise alongside troponin for ACS risk stratification.
Why the study?
Although troponin is the reference biomarker in acute coronary syndromes, other biomarkers may improve sensitivity and prognostic information but require further prospective validation.
Do novel biomarkers improve diagnosis and risk stratification in patients with acute coronary syndromes compared to troponin alone?
Do novel biomarkers improve diagnosis and risk stratification in patients with acute coronary syndromes compared to troponin alone?
Answers are grounded in this paper and cite their sources.
While troponin remains the gold standard, novel biomarkers related to inflammation and renal function may offer additional prognostic value in acute coronary syndromes.
Biomarkers play an important role in the diagnosis and risk stratification of patients with ischemic heart disease. Currently, troponin continues as the reference biomarker in acute coronary syndromes. However, there are other biomarkers that have shown additional value in improving sensitivity and prognostic information. Several promising molecules are reviewed, some related to cardiomyocyte structure and others working as inflammatory and renal function markers. Although many biomarkers have been shown useful in some studies, further prospective studies are needed to establish their accurate usefulness in routine clinical practice.
No takes yet. Share an insight, caveat, or question.
Sanmartı́n et al. (2015) conducted a review in Acute coronary syndrome. Biomarkers was evaluated. Various biomarkers, including troponin and novel molecules related to inflammation and renal function, show promise for diagnosing and risk-stratifying acute coronary syndromes.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: